ArticleThe Journal of clinical investigation2004
Concordant morphologic and gene expression data show that a vaccine halts HER-2/neu preneoplastic lesions.
Article in The Journal of clinical investigation, 2004. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
28 citing papers in PubMed, 71 citations in OpenAlex.
- Role of ADCC, CDC, and CDCC in Vaccine-Mediated Protection against Her2 Mammary Carcinogenesis.Biomedicines · 2022Article
- Maternal Immunization: New Perspectives on Its Application Against Non-Infectious Related Diseases in Newborns.Vaccines · 2017Review
- A plant-expressed conjugate vaccine breaks CD4(+) tolerance and induces potent immunity against metastatic Her2(+) breast cancer.Oncoimmunology · 2016Article
- Bovine herpesvirus 4-based vector delivering a hybrid rat/human HER-2 oncoantigen efficiently protects mice from autochthonous Her-2Oncoimmunology · 2016Article
- The Promise of Preventive Cancer Vaccines.Vaccines · 2015Review
- Antitumor immunization of mothers delays tumor development in cancer-prone offspring.Oncoimmunology · 2015Article
- Critical roles of specimen type and temperature before and during fixation in the detection of phosphoproteins in breast cancer tissues.Laboratory investigation; a journal of technical methods and pathology · 2015Article
- Intradermal DNA Electroporation Induces Cellular and Humoral Immune Response and Confers Protection against HER2/neu Tumor.Journal of immunology research · 2015Article
- Microenvironment, oncoantigens, and antitumor vaccination: lessons learned from BALB-neuT mice.BioMed research international · 2014Review
- Early onset and enhanced growth of autochthonous mammary carcinomas in C3-deficient Her2/neu transgenic mice.Oncoimmunology · 2013Article
- p130Cas/Cyclooxygenase-2 axis in the control of mesenchymal plasticity of breast cancer cells.Breast cancer research : BCR · 2012Article
- 2011: the immune hallmarks of cancer.Cancer immunology, immunotherapy : CII · 2011Article
- Identification and characterization of a HER-2/neu epitope as a potential target for cancer immunotherapy.Cancer immunology, immunotherapy : CII · 2010Article
- Phase I active immunotherapy with combination of two chimeric, human epidermal growth factor receptor 2, B-cell epitopes fused to a promiscuous T-cell epitope in patients with metastatic and/or recurrent solid tumors.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2009Article
- Oncoantigens as anti-tumor vaccination targets: the chance of a lucky strike?Cancer immunology, immunotherapy : CII · 2008Article
- Phosphoinositide 3-kinase p110beta activity: key role in metabolism and mammary gland cancer but not development.Science signaling · 2008Article
- Amino-biphosphonate-mediated MMP-9 inhibition breaks the tumor-bone marrow axis responsible for myeloid-derived suppressor cell expansion and macrophage infiltration in tumor stroma.Cancer research · 2007Article
- Immune selective pressure and HLA class I antigen defects in malignant lesions.Cancer immunology, immunotherapy : CII · 2007Review
- Peptide vaccine given with a Toll-like receptor agonist is effective for the treatment and prevention of spontaneous breast tumors.Cancer research · 2007Article
- Inflammation and breast cancer. Inflammatory component of mammary carcinogenesis in ErbB2 transgenic mice.Breast cancer research : BCR · 2007Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors at 4 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
While much experimental data shows that vaccination efficiently inhibits a subsequent challenge by a transplantable tumor, its ability to inhibit the progress of autochthonous preneoplastic lesions is virtually unknown. In this article, we show that a combined DNA and cell vaccine persistently inhibits such lesions in a murine HER-2/neu mammary carcinogenesis model. At 10 weeks of age, all of the ten mammary gland samples from HER-2/neu-transgenic mice displayed foci of hyperplasia that progressed to invasive tumors. Vaccination with plasmids coding for the transmembrane and extracellular domain of rat p185neu followed by a boost with rp185neu+ allogeneic cells secreting IFN-gamma kept 48% of mice tumor free. At 22 weeks, their mammary glands were indistinguishable from those of 10-week-old untreated mice. Furthermore, the transcription patterns of the two sets of glands coincided. Of the 12,000 genes analyzed, 17 were differentially expressed and related to the antibody response. The use of B cell knockout mice as well as the concordance of morphologic and gene expression data demonstrated that the Ab response is the main mechanism facilitating tumor growth arrest. This finding suggests that a new way can be found to secure the immunologic control of the progression of HER-2/neu preneoplastic lesions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.